Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: EXPRESSION ; GROWTH ; INVASION ; proliferation ; HEPATOCELLULAR-CARCINOMA ; COLORECTAL-CANCER ; GASTRIC-CANCER ; PROMOTES ; MISSING-IN-METASTASIS ; MIM
    Abstract: Growth factors promote tumor growth and metastasis. We found that epidermal growth factor (EGF) induced a set of 22 microRNAs (miRNAs) before promoting the migration of mammary cells. These miRNAs were more abundant in human breast tumors relative to the surrounding tissue, and their abundance varied among breast cancer subtypes. One of these miRNAs, miR-15b, targeted the 3' untranslated region of MTSS1 (metastasis suppressor protein 1). Although xenografts in which MTSS1 was knocked down grew more slowly in mice initially, longer-term growth was unaffected. Knocking down MTSS1 increased migration and Matrigel invasion of nontransformed mammary epithelial cells. Overexpressing MTSS1 in an invasive cell line decreased cell migration and invasiveness, decreased the formation of invadopodia and actin stress fibers, and increased the formation of cellular junctions. In tissues from breast cancer patients with the aggressive basal subtype, an inverse correlation occurred with the high expression of miRNA-15b and the low expression of MTSS1. Furthermore, low abundance of MTSS1 correlated with poor patient prognosis. Thus, growth factor-inducible miRNAs mediate mechanisms underlying the progression of cancer.
    Type of Publication: Journal article published
    PubMed ID: 25783158
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 0942-0940
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The limitations and the indications of cerebral scintigraphy using 1131 labelled macroaggregates of serum albumen injected directly into the carotid are examined. The investigation was carried out in a total of 101 patients with benign and malignant tumours, haematomata, cystic lesions, and cerebral vascular insufficiency. The authors raise the possibility that this technique might be useful in the elucidation of the pathophysiology of the cerebral arteriolar and capillary circulation as well as in the evaluation of the efficacy of the collateral circulation when the carotid is occluded. The authors celieve that cerebral scintigraphy using MAA-I131 can be regarded as a useful complementary diagnostic procedure.
    Abstract: Résumé Les auteurs examinent les indications et les limites de la scintigraphie cérébrale à l'aide de macroagrégat d'albumine sérique marqué à l'iode 131 et injecté directement dans la carotide. Ils décrivent la façon de procéder dans 101 cas de: tumeurs bénignes et malignes, hématomes, kystes, lésions cérébrales par insuffisance circulatoire, et analysent les résultats obtenus. En outre, les auteurs envisagent la possibilité d'une utilisation de la méthode scintigraphique dans l'étude de la physio-pathologie de l'arbre cérébral artériolo-capillaire, ainsi que dans l'appréciation de la capacité de la circulation collatérale en cas d'occlusion de la carotide. Les auteurs déclarent, en s'appuyant sur leur expérience, que la scintigraphie à l'aide de MAA-J131 peut être considérée comme un examen complémentaire utile pour le diagnostic en neurologie.
    Notes: Zusammenfassung Es wird über den Wert und die Resultate der Hirnszintigraphie mit Jod131-markierten Eiweißmakroaggregaten aus denaturiertem Humanserumalbumin (MAA-J131) bei intraarterieller Injektion in die A. carotis berichtet. Diese Methode wurde bei 101 Patienten mit gutartigen und bösartigen Tumoren, Hämatomen, zystischen Prozessen und zerebralen Durchblutungsstörungen durchgeführt. Außerdem werden die Möglichkeiten aufgezeigt, mit Hilfe dieser Methode Aufschlüsse über die Pathophysiologie der Hirndurchblutung im Bereiche der Arterien und der Kapillaren sowie über die kollateralen Durchblutungsverhältnisse bei Karotisverschlüssen zu gewinnen. Die Methodik wird beschrieben. Die Verfasser betonen, daß sich die Hirnszintigraphie mit MAA-J131 als wertvolle zusätzliche neurodiagnostische Methode bewährt hat.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Publication Date: 2018-06-02
    Description: Background: Preclinical data suggest that metformin may reduce breast cancer incidence and improve cancer prognosis. However, the current evidence in observational studies is inconclusive. A systematic review and meta-analysis was conducted to assess the effect of metformin on the incidence of breast cancer and all-cause mortality in patients with type II diabetes (T2D). Methods: A literature search was performed on Medline, EMBASE, and the Cochrane library from inception to November 2016. Outcomes were incidence of breast cancer and all-cause mortality. Risk of bias and overall certainty of evidence was assessed using the Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development, and Evaluation (GRADE), respectively. Meta-analyses were performed using the most fully adjusted ORs or HRs and 95% confidence intervals (95% CI) as effect measures. Results: A total of 12 observational studies were included for breast cancer incidence and 11 studies for all-cause mortality. No significant association was found between metformin exposure and incidence of breast cancer (OR = 0.93; 95% CI, 0.85–1.03; I 2 = 35%). A 45% risk reduction was observed for all-cause mortality (HR = 0.55; 95% CI, 0.44–0.70; I 2 = 81%). Presence of publication bias is strongly suspected for both outcomes using Egger's funnel plots. Conclusions: The use of metformin may improve overall survival in patients with T2D and breast cancer. No effect of metformin on the incidence of breast cancer was observed. Interpretation of results is limited by the observational nature of the studies and resulting biases. Impact: Clinical trials are warranted to determine the role of metformin in breast cancer risk reduction and prognosis. Cancer Epidemiol Biomarkers Prev; 27(6); 627–35. ©2018 AACR .
    Print ISSN: 1055-9965
    Electronic ISSN: 1538-7755
    Topics: Medicine
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...